Acute Monoblastic Leukemia (AmoL) Overview

Save information for later
Sign Up

Learn About Acute Monoblastic Leukemia (AmoL)

View Main Condition: Leukemia

What is the definition of Acute Monoblastic Leukemia (AmoL)?
Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML; see this term) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).
What are the alternative names for Acute Monoblastic Leukemia (AmoL)?
  • Acute monoblastic leukemia
  • AML M5
  • AML-M5
  • Acute monocytic leukemia
  • Acute myeloblastic leukemia type 5
Who are the top Acute Monoblastic Leukemia (AmoL) Local Doctors?
Dr. Ruthee-lu L. Bayer
Hematology Oncology | Oncology | Hematology
Dr. Ruthee-lu L. Bayer
Hematology Oncology | Oncology | Hematology

North Shore Health System Medical Faculty Group Practice Inc

27005 76th Ave, 
New Hyde Park, NY 
 (7.4 mi)
718-470-4449
Languages Spoken:
English

Ruthee-lu Bayer is a Hematologist Oncology specialist and an Oncologist in New Hyde Park, New York. Dr. Bayer and is rated as an Advanced provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). Her top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Craig E. Devoe
Hematology Oncology | Hematology
Dr. Craig E. Devoe
Hematology Oncology | Hematology

North Shore Health System Medical Faculty Group Practice Inc

27005 76th Ave, 
New Hyde Park, NY 
 (7.4 mi)
718-470-4449
Languages Spoken:
English
Offers Telehealth

Craig Devoe is a Hematologist Oncology specialist and a Hematologist in New Hyde Park, New York. Dr. Devoe and is rated as an Advanced provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). His top areas of expertise are Melanoma, Non-Hodgkin Lymphoma, Lynch Syndrome, Acute Promyelocytic Leukemia, and Tissue Biopsy.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Jen C. Wang
Hematology Oncology | Hematology
Dr. Jen C. Wang
Hematology Oncology | Hematology
5 E Walnut St, 
Long Beach, NY 
 (5.0 mi)
516-889-7447
Languages Spoken:
English
See accepted insurances

Jen Wang is a Hematologist Oncology specialist and a Hematologist in Long Beach, New York. Dr. Wang and is rated as an Experienced provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). His top areas of expertise are Lymphofollicular Hyperplasia, Hemochromatosis, Polycythemia Vera, Chronic T-Cell Leukemia (CTCL), and Bone Marrow Aspiration.

View All Doctors
What are the latest Acute Monoblastic Leukemia (AmoL) Clinical Trials?
A Phase II Study of Venetoclax (ABT-199) in Combination With Cladribine and Low-Dose Cytarabine Alternating With Azacitidine Plus Venetoclax in Newly Diagnosed Monocytic AML and Active-Signaling Mutated AML
A Phase II Study of Venetoclax (ABT-199) in Combination With Cladribine and Low-Dose Cytarabine Alternating With Azacitidine Plus Venetoclax in Newly Diagnosed Monocytic AML and Active-Signaling Mutated AML
Enrollment Status: Recruiting
Publish Date: January 20, 2025
Intervention Type: Procedure, Drug, Other
Study Phase: Phase 2

Summary: This phase II trial tests how well venetoclax with cladribine and cytarabine alternating with azacitidine and venetoclax works in treating patients with newly diagnosed monocytic acute myeloid leukemia (AML) and active signaling mutated AML. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein neede...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multicenter, Randomized, Controlled Clinical Trial of Venetoclax, Azacytidine Combined With Chidamide for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Patients That Are Ineligible for Intensive Chemotherapy
A Multicenter, Randomized, Controlled Clinical Trial of Venetoclax, Azacytidine Combined With Chidamide for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Patients That Are Ineligible for Intensive Chemotherapy
Enrollment Status: Recruiting
Publish Date: November 19, 2024
Intervention Type: Drug
Study Phase: Phase 2

Summary: This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center